Pfizer Beefs Up Blood Cancer Pipeline With Trillium Acquisition: See Highlights

Pfizer Inc PFE has agreed to acquire Trillium Therapeutics Inc TRIL for $18.50 per share, equivalent to an implied equity value of $2.26 billion.
The offer price represents a 118% premium to the 60-day weighted average price for Trillium.
Trillium's portfolio includes biologics include immuno-oncology product candidates.
Its two lead molecules, TTI-622 and TTI-621, block the signal-regulatory protein α (SIRPα)–CD47 axis, emerging as a key immune checkpoint in hematological malignancies.
TTI-622 and TTI-621 are SIRPα-Fc fusion proteins currently in Phase 1b/2 development across several indications, focusing on hematological malignancies.
Related Content: Trillium Therapeutics' CD47 Assets Show Continued Anti-Tumor Activity In Hematologic Malignancies.
Pfizer will conduct a webcast at 10:00 a.m. ET today.
Price Action: TRIL stock soared 191.50% at $17.75, and PFE stock is up 2.94% at $50.15 during the premarket session on the last check Monday.